Sovereign capital, guaranteed offtake, and localization mandates are reshaping how biotech deals get structured in the Gulf, ahead of the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026, 14 to 16 September, where 59 agreements have been signed across three editions.
For an investor or business development lead looking at the Gulf Cooperation Council (GCC) for the first time, the region can appear unfamiliar. The dominant capital is sovereign rather than institutional or venture. Government procurement often functions as the anchor customer rather than a downstream buyer. And the investment case is frequently built on import substitution and localization mandates rather than on novel asset value.
That structure differs from Western biotech clusters, and it offers advantages the venture model does not, particularly for capital-intensive manufacturing and infrastructure.
The Gulf’s place in global pharma strategy
For global pharmaceutical companies, the Gulf sits at a useful point on the map between Europe, Asia, and Africa, with the logistics infrastructure to serve as a distribution and manufacturing base well beyond its own borders. Novo Nordisk’s decision in May 2026 to build a regional distribution center in the UAE illustrates the logic: one of three such hubs the company operates worldwide, intended to serve up to 70 countries across the Gulf, Africa, and Central Asia, and to support treatment access for more than 2.6 million patients. Saudi Arabia shows the same pattern, from Pfizer’s manufacturing facility at King Abdullah Economic City to Ministry of Health agreements with Sanofi to localize insulin production, framed explicitly around export potential to wider Middle East markets.
The capital behind that logic is structurally distinct. EY’s analysis of Middle East and North Africa sovereign wealth funds found the region holds the world’s largest concentration of sovereign-owned assets relative to GDP, at more than 1.4 times as of 2024, against roughly 0.1 times in Europe and Asia. That capital operates on a longer horizon than venture capital and is deployed alongside explicit government strategy. For a multinational partner, patient capital combined with policy alignment is a distinct proposition, not a regional variant of the venture-backed model.
In Saudi Arabia, this model is increasingly being shaped by the National Biotechnology Strategy, which sets the Kingdom’s ambitions for biotechnology through 2030 and 2040. Its priorities include vaccines, biomanufacturing and localization, genomics, and plant optimization. H.E. Prof. Bandar Al-Knawy, Chief Executive Officer of the Ministry of National Guard Health Affairs and President of King Saud bin Abdulaziz University for Health Sciences, has emphasized the role of research, localization, industrial capability, and public-private partnerships in advancing these national priorities. For investors, that connection matters because many of the deal structures emerging in the Kingdom translate national biotechnology priorities into commercial capacity.
What the deal data shows
The clearest published dataset on GCC healthcare investment comes from JLL, which recorded close to 400 transactions across the region between 2021 and April 2025. Saudi Arabia and the UAE accounted for approximately 92 percent of that activity, with the UAE recording 198 deals and Saudi Arabia 170. The composition included 170 early-stage funding rounds, 91 mergers and acquisitions, and 27 initial public offerings.
That dataset is worth reading precisely. JLL’s sub-segment breakdown shows clinics and outpatient services accounting for 99 transactions and hospitals for 42, while pharmaceuticals account for 25 and biotechnology for 15. Therapeutics and platform biotechnology sit earlier on the investment curve than the wider healthcare sector. The region’s capital infrastructure and deal-making experience are already established at scale in adjacent segments, with clear headroom still available in biotechnology specifically.
Who is actually deploying capital
Sovereign and state-backed vehicles are the largest source. Lifera, the contract development and manufacturing organization established in 2023 and wholly owned by the Public Investment Fund, is the clearest example of sovereign capital deployed to build industrial capability directly rather than to take financial positions. That changes the counterparty: a sovereign-owned manufacturer building against a national localization target behaves differently from a commercial CDMO optimizing for utilization.
Government research funding runs through the Research, Development and Innovation Authority and related programs, including the Saudi Innovation Grants Program launched in December 2024, which provides non-dilutive funding to small and medium enterprises. Domestic venture capital is building alongside it: Beta Lab reported more than 200 funding applications in a single year, the majority from international startups. International capital is also entering through structured vehicles. At a previous Riyadh Global Medical Biotechnology Summit (RGMBS), SBI Holdings signed with the Ministry of Investment, KAIMRC, and BIM Ventures to launch a fund directing 50 million dollars into Japanese biotechnology startups at KAIMRC.
The structures that make deals work
Guaranteed offtake agreements are the single most consequential mechanism. When government commits to purchase a defined output volume, a manufacturing investment converts from a demand-risk bet into a capacity-delivery problem. For biologics and vaccines, where facility costs are high, that changes how the investment is underwritten.
Beyond offtake, the incentive stack includes tax credits of up to 50 percent on Saudi worker payroll and training for ten years, salary support through the Human Resources Development Fund, and special economic zones offering tax reductions and eased foreign talent rules. Technology transfer structures recur throughout: an international partner brings capability, a local entity builds and operates, and government procurement underwrites demand.
Regulatory predictability supports all of this. The Saudi Food and Drug Authority has been benchmarked by the World Health Organization at Maturity Level 4, the highest classification, and has published dedicated frameworks for advanced therapy medicinal products, including a classification guideline through which developers can request formal advice before clinical data exists. For an investor, regulatory pathway clarity is a direct input into risk pricing.
Institutional infrastructure is being built alongside the regulatory framework. The Riyadh Biocentral Foundation, approved as a non-profit entity under the Royal Commission for Riyadh City with a board chaired by the Crown Prince, carries a mandate covering biotechnology zones and facilities, incubation of early-stage projects, and partnerships with international biotech centers. For a company weighing a physical footprint in the Kingdom, that is the body responsible for the site and cluster infrastructure it would occupy.
What the RGMBS deal record shows
Across its first three editions, RGMBS has generated 59 agreements. The 2024 edition alone produced 40, with associated deal value above 100 million dollars.
The composition is more instructive than the count. The 2024 agreements spanned counterparties across the United States, Germany, Japan, China, and Saudi Arabia, covering cell and gene therapy, AI-based diagnostics, RNA technologies, vaccines and biosimilars, stem cells, precision medicine, and research infrastructure. Most were structured as memoranda of understanding between KAIMRC and an international partner. That is the prevailing model: the national research institution acts as anchor counterparty, and international organizations partner into its infrastructure and patient access rather than building independently. For a business development lead, that is the practical entry pattern.
Activity since has continued along the same lines. SPIMACO, the Kingdom’s largest vertically integrated pharmaceutical manufacturer, has established a wholly owned subsidiary, SPIMACO Bio, to develop and manufacture biological, gene, and cell therapy products, framed explicitly around localization and technology transfer. On the public markets, Sudair Pharmaceutical Company has filed with the Capital Market Authority to offer shares on the main market, following Jamjoom Pharma in 2023 and Avalon Pharma in 2024. For an investor, the relevant signal is that Saudi pharmaceutical assets now have a visible domestic exit route, not only a partnering one.
Where these conversations happen next
RGMBS 2026 takes place in Riyadh from 14 to 16 September. The investment theme runs across Day 2, covering AI-enabled biotechnology platforms, vaccine funding models, and a session on de-risking investment in biomanufacturing that addresses the offtake, public-private partnership, and blended finance structures described above. The program opens with a session on the National Biotechnology Strategy, which sets the policy targets most of this capital is deployed against, followed by a panel on global partnerships in biotech. Alongside the stage program, the summit runs structured business matchmaking and a dedicated agreement signing area.
If you are assessing the Gulf as a manufacturing base, a partnering market, or a source of capital, the questions above get answered faster in a room than on a call. The people who set the localization targets, the people who underwrite the offtake, and the people who sign the agreements are in the same building for three days.
RGMBS 2026 runs 14 to 16 September 2026 in Riyadh. The full scientific program and delegate registration are at rgmbs.org.
Sponsored content is written and provided to BioSpace by the advertiser. It is published with the advertiser’s approval without contribution from BioSpace’s editorial and insights teams.